Preventive Breast Screening

What is preventive screening?

Preventive breast screening involves the systematic clinical and imaging surveillance of asymptomatic women, with the goal of detecting pathological changes at a preclinical stage.

Early diagnosis:

• allows more conservative surgical interventions,
• reduces the need for extensive treatments,
• significantly improves prognosis and survival rates.

Preventive screening is a fundamental pillar in the modern management of breast cancer.

When does preventive screening begin?

International guidelines recommend:

• Clinical breast examination: annually from the age of 20.
• Mammography: annually from the age of 40 for the general population.
• For high-risk women (strong family history, known genetic mutation, prior chest radiation): screening should begin at an earlier age and often combines multiple imaging modalities.

Risk assessment is individualized, taking into account: family history, gynecological history, age at menarche and menopause, childbearing history, and hormone therapy.

Personalization of preventive screening is essential.

What examinations does preventive screening include?

Preventive breast screening is a fundamental factor in reducing breast cancer mortality and is based on systematic, organized, and evidence-based surveillance of women, even in the absence of symptoms.

The goal of screening is not merely to detect the disease, but to diagnose it at an early, curable stage, where treatment options are more numerous, less invasive, and carry an excellent prognosis.

The modern approach is based on combining clinical evaluation with appropriate imaging modalities, individualized according to age, personal and family history, and breast density.

Clinical Breast Examination

Clinical examination is the first step in preventive assessment. It includes taking a detailed medical history, with emphasis on risk factors, hormonal history, previous breast conditions, and family history of malignancy.

This is followed by visual inspection of the breasts in different arm positions, evaluating symmetry, skin changes, and the nipple, and then systematic palpation of the breast tissue and axillary lymph nodes.

Clinical examination can identify palpable lesions, skin changes, or nipple discharge. However, it is not sufficient as the sole screening method, since many early-stage malignancies are non-palpable. For this reason, clinical examination functions as a complement to imaging modalities, while regular breast self-examination helps you become familiar with the normal texture of your breasts between scheduled appointments.

Mammography

Mammography is the primary and most evidence-based method of preventive screening. Large international studies, as well as the World Health Organization, recognize that its systematic application significantly reduces breast cancer mortality.

The examination can detect microcalcifications, non-palpable masses, and early-stage malignancies before they become clinically apparent. This early detection often allows breast preservation and avoidance of extensive surgical procedures.

Modern digital mammography provides high image resolution with low radiation dose. Tomosynthesis (3D mammography) further improves diagnostic accuracy, particularly in women with increased breast density, reducing both false-positive and false-negative results.

The age at which screening begins and its frequency are individualized; however, in the general population, annual or biennial screening is recommended from the age of 40, in accordance with international guidelines.

Breast Ultrasound

Ultrasound is a complementary imaging method, particularly useful in women with dense breasts, where the sensitivity of mammography may be reduced.

It does not use ionizing radiation and allows differentiation between cystic and solid lesions, while also providing precise guidance for biopsies when needed.

It does not replace mammography within organized screening programs but is integrated into the individualized assessment of each woman.

Breast MRI

Breast MRI is characterized by high sensitivity in detecting malignancy. It is primarily used in high-risk women (such as carriers of genetic mutations), in cases with ambiguous imaging findings, or as part of preoperative planning.

It is not a routine examination for the general population, as its high sensitivity is accompanied by lower specificity, which may lead to unnecessary interventions if there is no clear indication.

The indication for MRI is always determined after specialized medical evaluation.

Management of Screening Findings

It is important to emphasize that the majority of findings detected during preventive screening are benign, such as benign breast conditions. The identification of a finding does not automatically imply malignancy.

In the case of a suspicious imaging abnormality, additional evaluation, short-interval follow-up, or histological confirmation through biopsy may be recommended. This process aims at diagnostic accuracy and the avoidance of both overtreatment and delayed diagnosis.

A recommendation for further investigation is part of an organized, safe, and scientifically controlled process.

The Importance of Early Diagnosis

When breast cancer is diagnosed at an early stage, cure rates are remarkably high. In most cases, surgical breast preservation is possible, and overall treatment interventions are less burdensome.

Prevention is not based on fear, but on knowledge and systematic follow-up. An informed woman, in collaboration with her specialized physician, can make evidence-based decisions about her health with confidence and composure.